Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 907828 versus doxorubicin as first-line treatment for advanced dedifferentiated liposarcoma
CTR20222584Phase 3Completed
- Sponsor
- 不适用/ 勃林格殷格翰(中国)投资有限公司
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brigimadlin in dedifferentiated liposarcoma (DDL), sponsored by 不适用/ 勃林格殷格翰(中国)投资有限公司. Started Dec 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on CTR20222584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222584.